Ország: Írország
Nyelv: angol
Forrás: HPRA (Health Products Regulatory Authority)
Tadalafil
Accord Healthcare Limited
G04BE; G04BE08
Tadalafil
20 milligram(s)
Film-coated tablet
Product subject to prescription which may not be renewed (A)
Drugs used in erectile dysfunction; tadalafil
Marketed
2016-05-20
PACKAGE LEAFLET: INFORMATION FOR THE USER Tadalafil 20 mg film-coated tablets Tadalafil READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor, or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Tadalafil is and what it is used for 2. What you need to know before you take Tadalafil 3. How to take Tadalafil 4. Possible side effects 5. How to store Tadalafil 6. Contents of the pack and other information 1. WHAT TADALAFIL IS AND WHAT IT IS USED FOR Tadalafil contains the active substance tadalafil which belongs to a group of medicines called phosphodiesterase type 5 inhibitors. Tadalafil is used to treat: ERECTILE DYSFUNCTION IN ADULT MEN : This is when a man cannot get, or keep a hard, erect penis suitable for sexual activity. Tadalafil has been shown to significantly improve the ability of obtaining a hard erect penis suitable for sexual activity. Following sexual stimulation Tadalafil works by helping the blood vessels in your penis to relax, allowing the flow of blood into your penis. The result of this is improved erectile function. Tadalafil will not help you if you do not have erectile dysfunction. It is important to note that Tadalafil does not work if there is no sexual stimulation. You and your partner will need to engage in foreplay, just as you would if you were not taking a medicine for erectile dysfunction. PULMONARY ARTERIAL HYPERTENSION IN ADULTS : It works by helping the blood vessels around your lungs relax, improving the flow of blood into your lungs. The result of this is an improved ability to do physical activity. 2. WHAT Olvassa el a teljes dokumentumot
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Tadalafil 20 mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 20 mg tadalafil. Excipient(s) with known effect: Lactose (as monohydrate) Each 20 mg film-coated tablet contains 367.584 mg lactose (as monohydrate). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet. Yellow, capsule shaped, approximately 14.3 mm in length and 7 mm in width, biconvex, bevelled edged, film coated tablet, debossed with "T 20" on one side and plain on other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of erectile dysfunction in adult males. In order for tadalafil to be effective for the treatment of erectile dysfunction, sexual stimulation is required. It is indicated in adults for the treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity (see section 5.1). Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Erectile dysfunction in adult Men_ In general, the recommended dose is 10 mg taken prior to anticipated sexual activity and with or without food. In those patients in whom tadalafil 10 mg does not produce an adequate effect, 20 mg might be tried. It may be taken at least 30 minutes prior to sexual activity. The maximum dose frequency is once per day. Tadalafil 10 mg and 20 mg is intended for use prior to anticipated sexual activity and it is not recommended for continuous daily use. _Pulmonary arterial hypertension_ Treatment should only be initiated and monitored by a physician experienced in the treatment of PAH. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ __ Olvassa el a teljes dokumentumot